文献速递胰腺与胆道疾病

伴与不伴既往急性胰腺炎的慢性胰腺炎患者代谢后遗症及全因死亡率:一项全国性人群队列研究

Metabolic Sequelae and All-Cause Mortality in Chronic Pancreatitis With and Without Prior Acute Pancreatitis: A Nationwide Population-Based Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2024-04-08

该研究利用丹麦全国健康登记数据,纳入2000至2018年9655例新发慢性胰腺炎患者,其中3913例(40.5%)有既往急性胰腺炎。与无既往急性胰腺炎者相比,有既往急性胰腺炎者死亡风险降低(HR 0.79,95%CI 0.74-0.84),胰腺炎后糖尿病风险升高(HR 1.53,95%CI 1.38-1.69),外分泌胰腺功能障碍和骨质疏松风险无总体差异。

要点

  • 慢性胰腺炎患者中40.5%有既往急性胰腺炎,多数患者无既往急性胰腺炎发作。
  • 有既往急性胰腺炎者死亡风险降低(HR 0.79,95%CI 0.74-0.84),主要限于诊断后初期。
  • 有既往急性胰腺炎者胰腺炎后糖尿病风险升高(HR 1.53,95%CI 1.38-1.69),持续可达十年。

核心结论

  • 多数慢性胰腺炎患者无既往急性胰腺炎发作,提示急性胰腺炎致敏胰腺并非慢性胰腺炎发展的必要条件。
  • 伴与不伴既往急性胰腺炎的慢性胰腺炎患者具有不同的胰腺炎后糖尿病和全因死亡风险特征。

研究设计与样本

  • 全国性人群队列研究,利用丹麦全国健康登记数据识别2000至2018年所有18岁及以上丹麦居民中新发慢性胰腺炎患者。
  • 共纳入9655例慢性胰腺炎患者,按慢性胰腺炎诊断前有无急性胰腺炎病史分层。
  • 采用多变量Cox比例风险模型计算代谢后遗症和全因死亡的风险比(HR)及95%置信区间(CI)。

主要发现

  • 9655例慢性胰腺炎患者中,3913例(40.5%)有既往急性胰腺炎诊断。
  • 与无既往急性胰腺炎者相比,有既往急性胰腺炎者死亡风险降低(HR 0.79,95%CI 0.74-0.84),主要限于慢性胰腺炎诊断后初期。
  • 与无既往急性胰腺炎者相比,有既往急性胰腺炎者胰腺炎后糖尿病风险升高(HR 1.53,95%CI 1.38-1.69),持续可达慢性胰腺炎诊断后十年。
  • 外分泌胰腺功能障碍风险无总体差异(HR 0.97,95%CI 0.87-1.07),骨质疏松风险无总体差异(HR 0.87,95%CI 0.74-1.02)。

关键数值与推荐

  • 有既往急性胰腺炎者 vs 无既往急性胰腺炎者:全因死亡 HR 0.79(95%CI 0.74-0.84)。
  • 有既往急性胰腺炎者 vs 无既往急性胰腺炎者:胰腺炎后糖尿病 HR 1.53(95%CI 1.38-1.69)。
  • 有既往急性胰腺炎者 vs 无既往急性胰腺炎者:外分泌胰腺功能障碍 HR 0.97(95%CI 0.87-1.07)。
  • 有既往急性胰腺炎者 vs 无既往急性胰腺炎者:骨质疏松 HR 0.87(95%CI 0.74-1.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The purpose of this study was to investigate the risk of metabolic sequelae and all-cause mortality in a population-based cohort of chronic pancreatitis (CP) patients with and without prior acute pancreatitis (AP). METHODS: We used nationwide health registries to identify all Danish residents (18 years and older) with incident CP from 2000 to 2018. Information on AP/CP diagnoses, metabolic sequelae (post-pancreatitis diabetes mellitus [PPDM], exocrine pancreatic dysfunction, and osteoporosis), and all-cause mortality were obtained from Danish national health registries. CP cases were stratified based on the presence of AP before CP diagnosis. The risk of metabolic sequelae and all-cause mortality was expressed as hazard ratios (HRs) with 95% confidence intervals (CIs), calculated using multivariate Cox proportional hazards models. RESULTS: A total of 9,655 patients with CP were included. Among patients with CP, 3,913 (40.5%) had a prior AP diagnosis. Compared with patients without a history of AP, patients with prior AP had a decreased risk of death (HR 0.79, 95% CI 0.74-0.84), which was largely confined to the initial period after CP diagnosis. Patients with prior AP had an increased risk of PPDM (HR 1.53, 95% CI 1.38-1.69), which persisted for up to a decade after CP diagnosis. No overall differences in risk were observed for exocrine pancreatic dysfunction (HR 0.97, 95% CI 0.87-1.07) and osteoporosis (HR 0.87, 95% CI 0.74-1.02). DISCUSSION: This nationwide study revealed that most of the patients with CP have no prior episode(s) of AP, indicating that an attack of AP sensitizing the pancreas is not essential for CP development. CP patients with and without prior AP have different risk profiles of PPDM and all-cause mortality.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Cook ME, Bruun NH, Davidsen L, et al. Metabolic Sequelae and All-Cause Mortality in Chronic Pancreatitis With and Without Prior Acute Pancreatitis: A Nationwide Population-Based Cohort Study. Am J Gastroenterol. 2024. PMID: 38587288. doi:10.14309/ajg.0000000000002799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。